Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Treatment of IgA nephropathy in children: a land without KDIGO guidance

Abstract

IgA nephropathy (IgAN) in children is no longer considered a rare and benign disease but a nephritis with different presentations and various outcomes. The decision to initiate a treatment and the therapeutic choice depend on the individual risk of progression. The Kidney Disease: Improving Global Outcomes (KDIGO) clinical guidelines in 2012 considered that the risk factors for progression of IgAN were similar in both children and adults and suggested in some conditions to follow the adult schedules. In 2017 a KDIGO Controversies Conference on management and treatment of glomerular diseases decided not to include an update in children with IgAN since the level of evidence of treatments in children was too scarce. Children can follow the indications for adults as far as the disease is similar in the various ages. This review is aimed at discussing why the KDIGO guidelines are poorly suitable to treat children with IgAN, and there is a need to develop new prediction models for progression of IgAN in children to guide selection of the cases to be treated. The identification of different risk levels in children with IgAN may personalize the choice of available drugs and support the use of new targeted therapies.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Coppo R (2018) Treatment of IgA nephropathy: Recent advances and prospects. Nephrol Ther. Suppl 1:S13-S21. doi:https://doi.org/10.1016/j.nephro.2018.02.010

  2. 2.

    Coppo R (2019) Pediatric IgA nephropathy in Europe. Kidney Dis (Basel) 5:182–188. https://doi.org/10.1159/000495751

  3. 3.

    Brunner FP, Fassbinder W, Broyer M, Oulès R, Brynger H, Rizzoni G, Challah S, Selwood NH, Dykes SR, Wing AJ (1988) Survival on renal replacement therapy: data from the EDTA registry. Nephrol Dial Transplant 3:109–122

  4. 4.

    Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis (2012) Immunoglobulin a nephropathy. Kidney Int Suppl 2:139–274

  5. 5.

    Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, Feehally J, Roberts IS, Amore A, Alpers CE, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator SN, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo AB, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2010) The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 77:921–927

  6. 6.

    Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, Wetzels JF, Cheung M, Wheeler DC, Winkelmayer WC, Rovin BH, Conference Participants (2019) Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 95:268–280. https://doi.org/10.1016/j.kint.2018.10.018

  7. 7.

    Chong LSH, Sautenet B, Tong A, Hanson CS, Samuel S, Zappitelli M, Dart A, Furth S, Eddy AA, Groothoff J, Webb NJA, Yap HK, Bockenhauer D, Sinha A, Alexander SI, Goldstein SL, Gipson DS, Raman G, Craig JC (2017) Range and heterogeneity of outcomes in randomized trials of pediatric chronic kidney disease. J Pediatr 186:110–117.e11. https://doi.org/10.1016/j.jpeds.2017.03.034

  8. 8.

    Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Sako M, Kaito H, Nozu K, Tanaka R, Iijima K, Yoshikawa N (2013) Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol 28:71–76

  9. 9.

    Cai Q, Xie X, Wang J, Shi S, Liu L, Chen Y, Lv J, Zhang H (2017) Severe adverse effects associated with corticosteroid treatment in patients with IgA nephropathy. Kidney Int Rep 2:603–609

  10. 10.

    Waldo FB, Alexander R, Wyatt RJ, Kohaut EC (1989) Alternate-day prednisone therapy in children with IgA-associated nephritis. Am J Kidney Dis 13:55–60

  11. 11.

    Welch TR, Fryer C, Shely E, Witte DP, Quinlan M (1992) Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin a glomerulonephritis. J Pediatr 121:474–477

  12. 12.

    Niaudet P, Murcia I, Beaufils H, Broyer M, Habib R (1993) Primary IgA nephropathies in children: prognosis and treatment. Adv Nephrol Necker Hosp 22:121–140

  13. 13.

    Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M (1999) A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 10:101–109

  14. 14.

    Kang Z, Li Z, Duan C, Wu T, Xun M, Ding Y, Zhang Y, Zhang L, Yin Y (2015) Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children. Pediatr Nephrol 30:1121–1129. https://doi.org/10.1007/s00467-014-3041-y

  15. 15.

    Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J, Carter B, Jung B, Hernandez G, Gipson D, Wyatt RJ (2015) Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 66:783–791. https://doi.org/10.1053/j.ajkd.2015.06.013

  16. 16.

    Cambier A, Rabant M, Peuchmaur M, Hertig A, Deschenes G, Couchoud C, Kolko A, Salomon R, Hogan J, Robert T (2018) Immunosuppressive treatment in children with IgA nephropathy and the clinical value of podocytopathic features. Kidney Int Rep 3:916–925

  17. 17.

    Coppo R (2017) Biomarkers and targeted new therapies for IgA nephropathy. Pediatr Nephrol 32:725–731. https://doi.org/10.1007/s00467-016-3390-9

  18. 18.

    Cambier A, Gleeson PJ, Monteiro R (2019) New therapeutic perspectives in IgA nephropathy developed in the young. Pediatr Nephrol. https://doi.org/10.1007/s00467-020-04475-w

  19. 19.

    Coppo R (2018) Towards a personalized treatment for IgA nephropathy considering pathology and pathogenesis. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfy338

  20. 20.

    Thompson A, Carroll K, A Inker L, Floege J, Perkovic V, Boyer-Suavet S, W Major R, I Schimpf J, Barratt J, Cattran DC, S Gillespie B, Kausz A, W Mercer A, Reich HN, H Rovin B, West M, Nachman PH (2019) Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 14:469–481. https://doi.org/10.2215/CJN.08600718

  21. 21.

    Yamagata K, Takahashi H, Tomida C, Yamagata Y, Koyama A (2002) Prognosis of asymptomatic hematuria and/or proteinuria in men. High prevalence of IgA nephropathy among proteinuric patients found in mass screening. Nephron 91:34–42

  22. 22.

    Coppo R, Gianoglio B, Porcellini MG, Maringhini S (1998) Frequency of renal diseases and clinical indications for renal biopsy in children (report of the Italian National Registry of Renal Biopsies in Children of the Italian Society of Nephrology). Nephrol Dial Transplant 13:293–307

  23. 23.

    Mizerska-Wasiak M, Turczyn A, Such A, Cichoń-Kawa K, Małdyk J, Miklaszewska M, Pietrzyk J, Rybi-Szumińska A, Wasilewska A, Firszt-Adamczyk A, Stankiewicz R, Szczepańska M, Bieniaś B, Zajączkowska M, Pukajło-Marczyk A, Zwolińska D, Siniewicz-Luzeńczyk K, Tkaczyk M, Gadomska-Prokop K, Grenda R, Demkow U, Pańczyk-Tomaszewska M (2016) IgA nephropathy in children: a multicenter study in Poland. Adv Exp Med Biol 952:75–84

  24. 24.

    Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, Fuiano L, Berg U, Topaloglu R, Bilginer Y, Gesualdo L, Polci R, Mizerska-Wasiak M, Caliskan Y, Lundberg S, Cancarini G, Geddes C, Wetzels J, Wiecek A, Durlik M, Cusinato S, Rollino C, Maggio M, Praga M, K Smerud H, Tesar V, Maixnerova D, Barratt J, Papalia T, Bonofiglio R, Mazzucco G, Giannakakis C, Soderberg M, Orhan D, Di Palma AM, Maldyk J, Ozluk Y, Sudelin B, Tardanico R, Kipgen D, Steenbergen E, Karkoszka H, Perkowska-Ptasinska A, Ferrario F, Gutierrez E, Honsova E (2017) Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatr Nephrol 32:139–150

  25. 25.

    Sevillano AM, Gutiérrez E, Yuste C, Cavero T, Mérida E, Rodríguez P, García A, Morales E, Fernández C, Martínez MA, Moreno JA, Praga M (2017) Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol 28:3089–3099. https://doi.org/10.1681/ASN.2017010108

  26. 26.

    Coppo R, Fervenza FC (2017) Persistent microscopic hematuria as a risk factor for progression of IgA nephropathy: new floodlight on a nearly forgotten biomarker. J Am Soc Nephrol 28:2831–2834. https://doi.org/10.1681/ASN.2017060639

  27. 27.

    Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76:534–545

  28. 28.

    Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J, IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants (2017) Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int 91:1014–1021. https://doi.org/10.1016/j.kint.2017.02.003

  29. 29.

    Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, Cattran D, Cook TH, Feehally J, Tesar V, Maixnerova D, Peruzzi L, Amore A, Lundberg S, Di Palma AM, Gesualdo L, Emma F, Rollino C, Praga M, Biancone L, Pani A, Feriozzi S, Polci R, Barratt J, Del Vecchio L, Locatelli F, Pierucci A, Caliskan Y, Perkowska-Ptasinska A, Durlik M, Moggia E, Ballarin JC, Wetzels JFM, Goumenos D, Papasotiriou M, Galesic K, Toric L, Papagianni A, Stangou M, Benozzi L, Cusinato S, Berg U, Topaloglu R, Maggio M, Ots-Rosenberg M, D'Amico M, Geddes C, Balafa O, Quaglia M, Cravero R, Lino Cirami C, Fellstrom B, Floege J, Egido J, Mallamaci F, Zoccali C (2018) Is there long-term value of pathology scoring in immunoglobulin a nephropathy? A validation study of the Oxford classification for IgA nephropathy (VALIGA) update. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfy302

  30. 30.

    Chakera A, MacEwen C, Bellur SS, Chompuk LO, Lunn D, Roberts ISD (2016) Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression. J Nephrol 29:367–375

  31. 31.

    Beckwith H, Medjeral-Thomas N, Galliford J, Griffith M, Levy J, Lightstone L, Palmer A, Roufosse C, Pusey C, Cook HT, Cairns T (2017) Mycophenolate mofetil therapy in immunoglobulin a nephropathy: histological changes after treatment. Nephrol Dial Transplant 32:i123–i128

  32. 32.

    Haas M, Verhave JC, Liu ZH, Alpers CE, Barratt J, Becker JU, Cattran D, Cook HT, Coppo R, Feehally J, Pani A, Perkowska-Ptasinska A, Roberts IS, Soares MF, Trimarchi H, Wang S, Yuzawa Y, Zhang H, Troyanov S, Katafuchi R (2017) A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol 28:691–701

  33. 33.

    Hou JH, LeWB CN, Wang WM, Liu ZS, Liu D, Chen JH, Tian J, Fu P, Hu ZX, Zeng CH, Liang SS, Zhou ML, Zhang HT, Liu ZH (2017) Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis 69:788–795

  34. 34.

    Shen XH, Liang SS, Chen HM, Le WB, Jiang S, Zeng CH, Zhou ML, Zhang HT, Liu ZH (2015) Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat biopsy based observation. J Nephrol 28:441–449

  35. 35.

    Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC, Oxford Derivation, North American Validation and VALIGA Consortia; Oxford Derivation North American Validation and VALIGA Consortia (2016) The MEST score provides earlier risk prediction in IgA nephropathy. Kidney Int 89:167–175

  36. 36.

    Bellur SS, Lepeytre F, Vorobyeva O, Troyanov S, Cook HT, Roberts IS, International IgA Nephropathy Working Group (2017) Evidence from the Oxford classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int 91:235–243

  37. 37.

    Edström Halling S, Söderberg MP, Berg UB (2012) Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant 27:715–722

  38. 38.

    Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Hashimura Y, Kaito H, Sako M, Iijima K, Yoshikawa N (2012) Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol 27:783–792

  39. 39.

    Le W, Zeng CH, Liu Z, Liu D, Yang Q, Lin RX, Xia ZK, Fan ZM, Zhu G, Wu Y, Xu H, Zhai Y, Ding Y, Yang X, Liang S, Chen H, Xu F, Huang Q, Shen H, Wang J, Fogo AB, Liu ZH (2012) Validation of the Oxford classification of IgA nephropathy for pediatric patients from China. BMC Nephrol 13:158. https://doi.org/10.1186/1471-2369-13-158

  40. 40.

    Shima Y, Nakanishi K, Hama T, Sato M, Mukaiyama H, Togawa H, Tanaka R, Kaito H, Nozu K, Iijima K, Yoshikawa N (2015) Biopsy timing and Oxford classification variables in childhood/adolescent IgA nephropathy. Pediatr Nephrol 30:293–299

  41. 41.

    Chen MG, Ye XH, Liang HY, Yang Q (2016) Clinical and pathological analysis of IgA nephropathy with acute kidney injury. Zhonghua Er Ke Za Zhi 54:610–613. https://doi.org/10.3760/cma.j.issn.0578-1310.2016.08.012

  42. 42.

    Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Er L, Espino-Hernandez G, Kim SJ, Reich HN, Feehally J, Cattran DC, International IgA Nephropathy Network (2019) Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med 179:942–952. https://doi.org/10.1001/jamainternmed.2019.0600

Download references

Author information

Correspondence to Rosanna Coppo.

Ethics declarations

Conflict of interest

No conflict of interest to declare.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Coppo, R. Treatment of IgA nephropathy in children: a land without KDIGO guidance. Pediatr Nephrol (2020). https://doi.org/10.1007/s00467-020-04486-7

Download citation

Keywords

  • IgA nephropathy in children
  • Treatment
  • KDIGO
  • Risk factors
  • MEST-C score
  • Prediction models